Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
Original languageEnglish
Pages (from-to)258-260
Number of pages3
JournalJournal of the American Academy of Dermatology
Issue number1
Publication statusPublished - 1 Jul 2021

Bibliographical note

Funding Information:
Funding sources: Celgene, now Amgen, provided funding in kind by providing apremilast through a compassionate use program.

Cite this